Successful treatment of cardiac involvement in dermatomyositis with rituximab

Zahi Touma, Thurayya Arayssi, Lina Kibbi, Abdel Fattah Masri

Research output: Contribution to journalArticle

37 Citations (Scopus)


Polymyositis and dermatomyositis are autoimmune inflammatory myopathies characterized by muscle weakness and inflammation. Current recommended therapy includes corticosteroids as mainstay treatment in addition to immunosuppressant. We present herein a 25 year-old female with dermatomyositis and cardiac involvement resistant to disease modifying anti-rheumatic drugs and anti-tumor necrosis factor-α. She was treated with anti-CD20 monoclonal antibody, rituximab. The patient demonstrated a remarkable clinical and laboratory response. B-cell depletion therapy with rituximab may be a viable option in patients with dermatomyositis and heart disease.

Original languageEnglish
Pages (from-to)334-337
Number of pages4
JournalJoint Bone Spine
Issue number3
Publication statusPublished - 1 May 2008



  • Cardiac disease
  • Dermatomyositis
  • Rituximab

ASJC Scopus subject areas

  • Rheumatology

Cite this